Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of 90Y-DOTATOC in somatostatin receptor-positive neuroendocrine tumors
2017-003268-11Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Nov 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 edotreotide in apudoma (NET) and neuroendocrine carcinoma (NEC), sponsored by European Institute of Oncology. Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
yttrium-90 edotreotide
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2017-003268-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003268-11.